We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
- Authors
Rosa, Fernanda; Schreiner, Andreas; Thomas, Pierre; Sherif, Tarek
- Abstract
Patients with schizophrenia or related disorders often switch antipsychotic therapy, most commonly due to lack of efficacy and side effects. The differences in anticipated efficacy and tolerability among atypical antipsychotics may drive switching behaviours. Switching to long-acting antipsychotics may improve adherence. Improving adherence is essential as relatively short medication gaps significantly increase the risk of schizophrenia hospitalizations. Long-term treatment with risperidone long-acting injectable (RLAI), the first available long-acting atypical antipsychotic, versus oral atypical antipsychotics showed better adherence with RLAI. Stable patients with schizophrenia or related disorders treated with a stable dose of antipsychotic showed improved efficacy when switched to flexible doses of RLAI. The most common reason for patients to switch from olanzapine to another antipsychotic is excessive weight gain. Metabolic dysfunction also occurs more commonly with olanzapine than with risperidone. Patients switching from olanzapine to risperidone experienced significant decreases in body weight, body mass index and triglyceride levels, whereas patients switching from risperidone to olanzapine experienced significant increases in body weight and triglyceride levels. The efficacy, tolerability and safety of RLAI in non-acute patients with schizophrenia or schizoaffective disorder previously treated with oral olanzapine needs to be explored.
- Publication
Clinical drug investigation, 2012, Vol 32, Issue 4, p267
- ISSN
1179-1918
- Publication type
Journal Article
- DOI
10.2165/11599080-000000000-00000